NCT06152809 2026-03-18CIML NK Cells With Venetoclax for AMLDana-Farber Cancer InstitutePhase 1 Recruiting10 enrolled
NCT06138587 2026-01-02Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell TransplantationDana-Farber Cancer InstitutePhase 1 Recruiting15 enrolled
NCT06001788 2025-12-03Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid LeukemiaKura Oncology, Inc.Phase 1 Recruiting171 enrolled
NCT04260022 2025-11-05Study of HQP1351 in Subjects With Refractory CML and Ph+ ALLAscentage Pharma Group Inc.Phase 1 Recruiting242 enrolled
NCT06501196 2025-09-24A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic SyndromeBlossomHill TherapeuticsPhase 1 Recruiting170 enrolled